• Focus: pathogenesis, prevention, diagnosis, treatment and prognosis of oncological diseases
  • Main scientific fields: molecular characterization of common tumors, including breast, prostate, colorectal, gastric and lung cancers enabling development of innovative early detection, therapeutic and monitoring strategies
  • Relevance: strong research expertise encompassing all the way from translational to clinical research of the most common cancers in Portugal and worldwide


Carmen Jerónimo

MD. PhD.

Coordinator: Carmen Jerónimo is currently the Director of the Portuguese Oncology Institute of Porto (IPO Porto) Research Center (CI-IPOP) (2021-) and Group Leader of the Cancer Biology & Epigenetics Group (2008-), as well as Scientific Coordinator of the institutional Biobank (2016-). Additionally, she is a Guest Full Professor at the Department of Pathology and Molecular Genetics (2020-) and Director of the Master Course in Oncology (2016-) of the School of Medicine & Biomedical Sciences (ICBAS)- University of Porto. She obtained the BSc in Biology (1994), the MSc in Oncology (1998), the PhD in Biomedical Sciences (2001), and the Habilitation/Aggregation in Pathology and Molecular Genetics (2011) from the University of Porto.

Fernando Schmitt

MD. PhD.

Fernando Schmitt is a Professor of Pathology at the Faculty of Medicine of the University of Porto, the head of the Molecular Pathology Unit at IPATIMUP, President of the Portuguese Society of Cytology, President of the International Society of Breast Pathology, and General Secretary of the International Academy of Cytology. He is widely considered a world-leading expert in cytopathology and breast cancer. He has authored over 500 papers in peer-review journals (h-index: 69) and 4 books on breast cancer, cytopathology and molecular pathology. Schmitt was the Diretor of the Laboratoire National de Santé of Luxemburg for 2 years, managing over 200 persons and participating actively in the definition of public health policies in that country. During the last decade, he has been distinguished with 3 major awards, 2 of them from international institutions.

Mário Dinis-Ribeiro graduated in Medicine and earned his Doctorate Degree and Aggregation from the Faculty of Medicine of the University of Porto (FMUP). He is a Senior Consultant and the Head of the Gastroenterology Department of the IPO-Porto, a Guest Full Professor at FMUP and the iGO Group Leader at CINTESIS. His research interests focus on improving early diagnosis and noninvasive management of gastrointestinal tumors. He leads several inter-institutional national and international projects with over 250 scientific articles published. He is a member of the Scientific Committee of the PhD programme in Clinical and Health Services Research at FMUP. He is currently the President of the European Society of Gastrointestinal Endoscopy and Co-Editor-in-Chief of the journal Endoscopy. He was the 2018 BIAL Award in Clinical Medicine winner and one of the authors of the work that won the 2016 Pfizer Award for Clinical Research.

Rui Henrique

MD. PhD.

Rui Henrique is an Anatomic Pathologist and the Chairman of the Board of Directors of the Portuguese Oncology Institute of Porto (IPO-Porto). He is also a Guest Full Professor at the Abel Salazar Institute of Biomedical Science (ICBAS) and a Senior Researcher at the IPO-Porto Research Centre. Henrique graduated in Medicine and received his Ph.D. in Medical Sciences (Molecular Pathology) with a thesis in part developed at Johns Hopkins University (USA). He has authored over 250 publications, mainly focused on Hematopathology and Uropathology, on the role of epigenetic alterations in tumorinogenesis, and the development of novel cancer biomarkers based on the epigenetic of tumors. He was the Director of the Department of Pathology and the Director of the Department of Education of IPO-Porto. He is often invited to collaborate with the Ministry of Health of Portugal as an expert adviser. He was the president of the Portuguese Society of Anatomical Pathology.